Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525280 | 0.86 | ALDH1A1 (0.47) | ALDH1A1KDM4EPOLBMAPTSMN1; SMN2 | |
| SCHEMBL5502854 | 0.82 | DYRK1B (0.40) | ALDH1A1KDM4EMAPTSMN1; SMN2DYRK1B | |
| SCHEMBL732383 | 0.82 | DYRK1B (0.40) | ALDH1A1KDM4EMAPTDYRK1BMEN1 | |
| SCHEMBL24839312 | 0.79 | MEN1 (0.41) | ALDH1A1KDM4EMAPTDYRK1BMEN1 | |
| SCHEMBL4389687 | 0.79 | ALDH1A1 (0.40) | ALDH1A1KDM4EPOLBMAPTSMN1; SMN2 | |
| SCHEMBL29935588 | 0.79 | ERN1 (0.47) | ALDH1A1KDM4EPOLBMAPTSMN1; SMN2 | |
| SCHEMBL4585191 | 0.79 | SMN1; SMN2 (0.47) | ALDH1A1KDM4EPOLBMAPTSMN1; SMN2 | |
| SCHEMBL4587473 | 0.79 | ERN1 (0.47) | ALDH1A1KDM4EPOLBMAPTSMN1; SMN2 | |
| SCHEMBL29935762 | 0.79 | SMN1; SMN2 (0.47) | ALDH1A1KDM4EPOLBMAPTSMN1; SMN2 | |
| SCHEMBL6201297 | 0.79 | NR4A2 (0.56) | ALDH1A1KDM4EPOLBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4374928-A2 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | The Brigham And Women's Hospital Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-3615538-B1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11654147-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11654147-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11654147-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230000869-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2023-01-05 | — | — | US | disclosed |
| US-20230000869-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2023-01-05 | — | — | US | disclosed |
| US-11026947-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11026947-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200179389-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-11 | — | — | US | disclosed |
| WO-2007136940-A2 | THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007103756-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| CN-101023080-A | Thiazolinone 4-monosubstituted quinolines | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | CN | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1797085-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006132739-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CHEN LI | 2006-03-23 | — | — | US | disclosed |
| WO-2006029861-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179389-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | BMPR2, BMP1, BMP2K | ALDH1A1 4733/4885KDM4E 1955/4885POLB 2862/4885 |
| US-20230000869-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | BMPR2, BMP1, BMP2K | ALDH1A1 4733/4885KDM4E 1955/4885POLB 2862/4885 |
| US-11654147-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | BMPR2, BMP1, BMP2K | ALDH1A1 4711/4885KDM4E 1912/4885POLB 2728/4885 |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CDK1, CDK14, CDK17 | ALDH1A1 3777/4885KDM4E 1106/4885POLB 725/4885 |
| US-11026947-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | BMPR2, BMP1, BMP2K | ALDH1A1 4711/4885KDM4E 1912/4885POLB 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.